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Abstract: 
Resect and discard refers to a paradigm for the management of colorectal adenomas 1-5 mm in size. In 
this paradigm, histology of colorectal polyps is predicted endoscopically based on surface features. 
Lesions that are ≤ 5 mm in size and predicted to be adenomas are resected endoscopically and discarded 
rather than submitted to pathology. Adenomas in this size range have an extremely low risk of cancer, 
and the cost savings of the resect and discard paradigm would be substantial. Artificial intelligence 
programs can improve the overall prediction for histology based on endoscopic imaging and reduce 
operator dependence in endoscopic predictions. Although meta-analyses have concluded that the 
accuracy of endoscopic prediction is sufficiently high to institute the resect and discard paradigm in 
clinical practice, actual implementation has faced several obstacles. These include lack of financial 
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incentives for endoscopists, perceived increased medical-legal risk compared to the current management 
paradigm of submitting all polyps to pathology, and local rules for tissue handling.  
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Introduction: What is resect and discard?  
Resect and discard is a proposal for a new paradigm for management of diminutive colorectal polyps 
encountered during colonoscopy (1). The current paradigm is to remove all diminutive polyps 
encountered, except when there are multiple hyperplastic appearing lesions in the rectosigmoid. In that 
instance, the usual care is to sample a few of the hyperplastic lesions, or to leave all of them in place. In 
the resect and discard paradigm, diminutive colorectal polyps are first assessed endoscopically to predict 
their histology. Diminutive lesions that appear both benign and adenomatous, are then resected and 
disposed of rather than submitted to pathology.  
The resect and discard paradigm depends on the ability of endoscopists to predict diminutive colorectal 
polyp histology accurately. This process generally involves the application of an endoscopic 
classification scheme for histology. The most commonly used and discussed scheme in clinical practice 
is the Narrow Band Imaging International Colorectal Endoscopic classification (NICE) which was 
developed for use in high definition non-magnifying Olympus colonoscopes and narrow band imaging 
(2) (Table 1). Although the NICE classification was developed for use with Olympus narrow band
imaging (NBI), it has been successfully applied using colonoscopes made by other Japanese 
manufacturers, and their respective alternative electronic chromoendoscopy formats. Recently, a system 
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analogous to NICE has been developed specifically for use with Fujinon colonoscopes and the blue light 
imaging (BLI) modality (3). The endoscopic appearance of (BLI) is qualitatively very similar to NBI, as 
is the BASIC classification (BLI Adenoma Serrated International Classification). The Kudo 
classification was developed for use in magnifying colonoscopes with chromoendoscopy (4). Although 
the structures described in the NICE and BASIC classifications may not be precisely the same as those 
described in the Kudo classification, it is widely accepted that lesions of the NICE type 1 correspond to 
Kudo types I and II, and the lesions of the NICE 2 variety (adenomas) represent the Kudo III and IV 
classes. Nice type 3, which is indicative of deep submucosal invasive cancer (5), corresponds to Kudo 
V.  
The NICE 1 classification represents both the hyperplastic polyps and the sessile serrated polyps (also
called sessile serrated adenomas and sessile serrated lesions). The NICE classification does not attempt 
to distinguish hyperplastic polyps (HPs) from sessile serrated polyps (SSPs), but it does make note that 
large open pits are a feature of sessile serrated polyps. The WASP classification (Working Group on 
Serrated Polyps) combines both surface details and gross morphologic features to distinguish 
hyperplastic polyps from sessile serrated polyps (6)(Table 2). The success with which the WASP 
classification can be applied to diminutive NICE type 1 lesions to distinguish hyperplastic polyp from 
sessile serrated polyp is currently unclear. 
The resect and discard paradigm was formalized in 2011 by an American Society for Gastrointestinal 
Endoscopy (ASGE) PIVI (Preservation and Incorporation of Valuable Endoscopic Innovation) (1). The 
PIVI proposed that resect and discard an appropriate paradigm for the management of diminutive 
colorectal polyps if the application of resect and discard in clinical studies, followed by assignment of 
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colonoscopy surveillance intervals based on endoscopic histologic predictions, corresponded with 
surveillance intervals based entirely on pathology in ≥ 90% of cases. The PIVI included both the resect 
and discard policy and a second policy in which a strategy was proposed to leave distal diminutive 
polyps in place with increased confidence in their hyperplastic pathology. In the latter policy, if the 
negative predictive value of endoscopic predictions for adenomas in the rectosigmoid was > 90%, then 
leaving these lesions in place was considered appropriate therapy. In clinical studies, achieving the 
resect and discard target has been somewhat more difficult than achieving the 90% threshold for 
negative predictive value for adenomas among diminutive rectosigmoid lesions (7). 
As a consequence of limited ability of endoscopic prediction to assign NICE type 1 lesions as 
hyperplastic versus sessile serrated polyps, the resect and discard policy has been basically proposed to
affect diminutive conventional adenomas throughout the colon. In this management paradigm, lesions 
predicted to be diminutive colorectal conventional adenomas anywhere in the colon could be 
documented by photography, resected, and discarded. Proximal to the sigmoid colon, NICE 1 lesions 
would be resected and submitted to pathology so that they could be accurately classified as HP versus 
SSP. For type 1 lesions in the rectosigmoid, they can be reasonably left in place. In a recent study, less 
than 2% of diminutive NICE type 1 lesions in the rectosigmoid were found to be SSPs by experienced 
pathologists (8).  
The risks of the resect and discard paradigm include the potential of an endoscopist to resect a 
diminutive cancer and discard it rather than submit it to pathology. Recent analyses suggest that the risk 
of this event is extremely low and in one large recent series, there were no cancers among > 30,000 
diminutive colorectal polyps (9). The decline in the prevalence of cancers seen in recent studies may 
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reflect the very large numbers of extremely flat lesions detected with modern high definition 
colonoscopes. The second risk is inaccurate assignment of surveillance intervals after colonoscopy. It is 
now widely held that failure to detect lesions is of considerably more importance for the development of 
interval cancer than is misclassification of surveillance intervals (10, 11). Surveillance intervals are both 
widely overused and underused in clinical practice (12, 13). Thus, the critical element to prevent interval 
cancers is high adenoma detection rates (ADRs) (10, 11). Current guidelines suggest that the group with 
1 or 2 adenomas < 10 mm in size can undergo colonoscopic surveillance at either 5 or 10 years (14). 
Since patients with normal colonoscopies are advised to undergo repeat screening colonoscopy at 10 
years, the use of surveillance intervals of 10 years means that resect and discard is considerably less 
likely to create errors when policies follow the 10-year interval for 1 or 2 adenomas < 10 mm in size. 
That group (1-2 adenomas less than 10 mm in size) constitutes about two thirds of the entire adenoma
bearing cohort (15). A third obstacle is the challenge of measuring the ADR if lesions are not submitted 
to pathology. ADR has emerged as the most important quality predictor in colonoscopy, and 
measurement rests on pathologic identification of conventional adenomas. However, about 15% of 
adenomas 1-3 mm in size removed and submitted to pathology are called normal by pathologists (16). 
This almost certainly results from failure to section the actual polyp tissue versus normal tissue around 
the polyp that was resected and submitted with the specimen, or fragmentation of the polyp during 
retrieval (17). Thus, current ADR measurements already underestimate ADR. A recent study found that 
photography could be used to accurately support ADR measures (18). Under the resect and discard 
policy, the record of an adenoma is a photograph that captures the features on which the prediction of 
adenoma was made, rather than a glass slide in the pathology department.  
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The benefit of resect and discard is primarily cost reduction. One cost analysis suggested a proposed 
savings of over $1 billion per year in the U.S. alone by the resect and discard proposal (19). Another 
more conservative cost analysis suggested a savings of $33 million (20). 
Evidence for resect and discard from clinical studies 
A large number of clinical studies have assessed the predictive value of endoscopic classification 
schemes for differentiating conventional adenomas from serrated class lesions (21-23), and applied these 
to determination of surveillance intervals. Meta-analyses conducted by independent groups (23), and by 
the technology assessment committee of the ASGE (24), have determined that narrow band imaging has 
been effectively used to reach both of the PIVI criteria, supporting the institution of the PIVI paradigms
in clinical practice. One feature seen in some of the available literature is that endoscopic experts tend to 
outperform community-based endoscopists in their predictions of histology (7, 22, 23).  
Obstacles to resect and discard 
The resect and discard policy is seldom implemented in clinical practice at the present time. This is true 
despite the development of a substantial amount of supportive evidence. This paradox reflects the reality 
that in order for a new medical management paradigm to move forward, the paradigm may require more 
than supportive evidence. Table 3 lists a number of factors that affect the acceptance of new 
management paradigms. In some cases, these factors can be more or much more important than the 
evidence supporting the paradigm. The first important factor affecting acceptance is whether some 
involved factions have reduced income as a result of the new paradigm. An excellent example of where 
 ©2019. Elsevier Inc. All rights reserved.
this factor determined the implementation of a new paradigm is endoscopist directed propofol for 
endoscopic procedures. The evidence that endoscopists could safely supervise the administration of 
propofol, and that the practice was cost effective, was overwhelming (25). Despite that, the anesthesia 
community effectively blocked implementation of endoscopist directed propofol, and arguably because 
of concerns over loss of income (26). In the case of resect and discard, potentially adversely affected 
factions include pathology as a specialty and endoscopists who own pathology laboratories. However, 
neither of these groups seems to be as politically powerful as the anesthesiology and nurse anesthetist 
communities, though they might block implementation of resect and discard at the national, state, or 
institutional levels. Furthermore, endoscopists implementing resect and discard in a fee for service 
model have no apparent financial incentive to perform endoscopic predictions. Although society in 
general and insurance companies in particular could benefit from resect and discard financially, there is
no financial reward in the U.S. for endoscopic prediction of histology. In Japan, this conundrum was 
solved by a national policy reimbursing endoscopists for the use of image enhanced endoscopy (IEE). 
Most experts agree that the prospects for reimbursement for IEE in the U.S. are low.  
A second important factor that can determine the outcome of a proposed paradigm is the associated or 
perceived medical-legal risk associated with a new paradigm. Here again the analogy with endoscopist 
directed propofol is apparent, since the administration of propofol provided no financial advantage to 
endoscopists and produced significant perceived and probably real medical-legal risk for endoscopists 
administering propofol. Similarly, many endoscopists perceive an increased medicolegal risk in the 
resect and discard policy. If a patient developed an interval cancer, an expert might opine that the 
resected lesion was a cancer, even though it is much more likely that the interval cancer arose from a 
separate missed lesion. In this regard, photography of each resected lesion would appear to provide 
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protection for endoscopists, but the actual outcome of medical legal actions seems potentially 
unpredictable.  
Due to these factors, the use of IEE for the specific purpose of resect and discard is not a U.S. Food and 
Drug Administration (FDA) approved indication for these technologies. Indeed, the FDA, which takes 
positions largely based on patient safety or perceptions of safety, seems unlikely to approve any 
technology that moves patients from the current paradigm toward one that is perceived as having 
increased risk, regardless of proposed cost savings. Additional questions for endoscopists include: how 
do I become trained in IEE? Do I need to have training in IEE to utilize resect and discard? Do I need to 
become credentialed in IEE? Do I need to establish an institutional policy regarding resect and discard? 
Do I need to establish a quality program for monitoring the accuracy of endoscopic predictions in resect
and discard? For all these reasons, and given the lack of a financial incentive to utilize resect and 
discard, it is easy to understand why the paradigm has made little progress. One solution for decreasing 
medical legal risk would be to video record all colonoscopic procedures, a policy that is becoming 
increasingly feasible and affordable.  
Artificial intelligence and resect and discard 
Obviously, image analysis has enormous potential for artificial intelligence (AI). Indeed, AI programs 
have already shown substantial accuracy for differentiating conventional adenomas from NICE type I 
lesion (27-38). Training deep learning programs to differentiate hyperplastic polyp from sessile serrated 
polyp is complicated by the high interobserver variation between pathologists in making this 
differentiation, which adds challenges for developing an effective AI program. 
 ©2019. Elsevier Inc. All rights reserved.
One very valuable aspect of AI predictions of diminutive colorectal polyp histology would be to 
eliminate the skill variability previously noted between academic expert endoscopists and community 
based endoscopists (7, 23). However, as noted above, this discrepancy in skill level in endoscopic 
interpretation is only part of the layer of obstacles arrayed against the resect and discard paradigm. 
However, AI would increase accuracy, improve documentation, and provide a support tool for 
endoscopists’ predictions. Again, for legal reasons, AI is likely to be considered an adjunct to predicting 
histology, analogous to the development of narrow band imaging as an adjunct to gastrointestinal 
imaging. 
Summary and conclusions 
The evidence that resect and discard can be effectively applied to conventional adenomas throughout the 
colorectum during colonoscopy is already present, particularly for expert endoscopists. Artificial 
intelligence holds the promise of reducing previously observed differences between expert endoscopists 
and other endoscopists in achieving accurate endoscopic prediction. AI would also improve 
documentation and serve as a useful support tool for endoscopists’ prediction of histology. Of course, AI 
will serve as an important adjunctive imaging tool for a variety of endoscopic decisions that are based 
on image enhanced endoscopy that go beyond resect and discard. However, the ultimate emergence of 
the resect and discard paradigm, which from the perspective of logic and effective use of resources 
seems inevitable, will depend on other factors such as changes in reimbursement structure and 
development of effective medical-legal protections.  
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Table 1. NICE classification 
Type 1 Type 2 Type 3 
Color Same or lighter than 
background 
Browner relative to 
background (verify color 
arises from vessels) 
Brown to dark brown relative 
to background; sometimes 
patchy whiter areas 
Vessels None, or isolated lacy vessels 
may be present coursing across 
the lesion 
Thick brown vessels 
surrounding white structures† 
Has area(s) with markedly 
distorted or missing vessels 
Surface pattern Dark spots surrounded by 
white 
Oval, tubular, or branched 
white structures† surrounded 
by brown vessels 




Hyperplastic or sessile serrated 
polyp (SSP) 
Adenoma Deep submucosal invasive 
cancer 
†structures may represent the pits and epithelium of the crypt opening. 
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Table 2. Features of SSPs in the WASP classification 
SSP: Sessile serrated polyp 
WASP: Workgroup on serrated polypS and Polyposis 
Table 3. Factors determining forward movement of new medical paradigms




Evidence to support the paradigm 
Cost-effectiveness of the new paradigm relative to the established paradigm 
Financial incentives and disincentives for specialties involved in the new and old paradigms 
Political influence of involved parties 
Perceived medical-legal risk in new versus old paradigms 
National, state, and institutional rules affecting the new paradigm 
 ©2019. Elsevier Inc. All rights reserved.
Abbreviations 
NICE - Narrow Band Imaging International Colorectal Endoscopic 
NBI - narrow band imaging 
BLI - blue light imaging 
BASIC - BLI Adenoma Serrated International Classification  
WASP - Workgroup serrAted polypS and Polyposis 
ASGE - American Society for Gastrointestinal Endoscopy 
PIVI - Preservation and Incorporation of Valuable endoscopic Innovation 
HP - hyperplastic polyp 
SSP - sessile serrated polyp 
mm - millimeter 
ADR - adenoma detection rate 
IEE - image enhanced endoscopy   
U.S. FDA - United States Food and Drug Administration 
AI- artificial intelligence 
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